VIDEO: AACE tailors new fatty liver guideline to endocrinologists

Issue: June 2022

ByJonathan D. Leffert, MD, FACP, FACE, ECNU

SAN DIEGO — In this video exclusive, Jonathan D. Leffert, MD, talks with Kenneth Cusi, MD, FACP, FACE, about the new American Association of Clinical Endocrinology nonalcoholic fatty liver disease guideline tailored for endocrinologists.

Leffert is managing partner at North Texas Endocrine Center and past president of AACE. Cusi is chief of the division of endocrinology, diabetes and metabolism at the University of Florida in Gainsville. Both are Endocrine Today Editorial Board Members.

They discuss the great prevalence of NAFLD among people with type 2 diabetes, how to diagnose NAFLD and medications on the horizon for treatment.

Published by:

Sources/Disclosures

Collapse

Disclosures: Cusi reports receiving research support as principal investigator for the University of Florida from Cirius Therapeutics, Echosens, Inventiva, Novartis International, Novo Nordisk, Poxel and Zydus Pharmaceuticals, and serving as a consultant for Allergan, Altimmune, Arrowhead Pharmaceuticals, AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim, Coherus BioSciences, Eli Lilly and Co., Fractyl Health, Hanmi Healthcare, Genentech, Gilead Sciences, Intercept Pharmaceuticals, Janssen Pharmaceuticals, Pfizer, Prosciento, Madrigal Pharmaceuticals and Novo Nordisk. Leffert reports no relevant financial disclosures.

American Association of Clinical Endocrinology Annual Meeting

Read more

VIDEO: AACE tailors new fatty liver guideline to endocrinologists

Related Content